A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Tetra-specific Antibody GNC-038 in Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Listed as NCT05192486, this PHASE1/PHASE2 trial focuses on Diffuse Large B-cell Lymphoma and remains ongoing. Sponsored by Sichuan Baili Pharmaceutical Co., Ltd., it has been updated 10 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Oct 2025 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2025 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2024 — Jan 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 5 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2023 — May 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2022 — Feb 2023 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sichuan Baili Pharmaceutical Co., Ltd.
- SystImmune Inc.
For direct contact, visit the study record on ClinicalTrials.gov .